GLPwatch

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

NCT03789578 · Completed

Last updated 2026-05-28

This study is testing how the experimental drug Insulin 287 and the approved drug semaglutide work in the bodies of adults with type 2 diabetes when taken alone or together.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 30 people
Who can join Ages 18–64 · all sexes
Timeline Started 2019-01 · est. completion 2019-10
Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT03789578 ↗

Description as written by the study sponsor.

The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when given alone or together. Participants will get 3 study medicines at 3 different time points: 1) a combination of semaglutide plus insulin 287, 2) insulin 287 alone and 3) semaglutide alone. The order in which participants get them is decided by chance. Participants will get all medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks. The study will last for about 19 to 32 weeks in total.

Treatments tested

Main thing measuredAUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03789578 ↗